Biogen (BIIB) Gains from Investment Securities (2009 - 2026)

Biogen (BIIB) has reported Gains from Investment Securities for 18 consecutive years, with $20.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 150.12% year-over-year to $20.5 million; the TTM figure through Mar 2026 stood at $53.7 million (up 120.24% YoY), while the FY2025 annual figure was -$19.3 million, up 87.91% from the prior year.
• Gains from Investment Securities came in at $20.5 million for Q1 2026 at Biogen, up from $14.4 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $503.7 million in Q3 2022, with the low at -$513.3 million in Q4 2022.
• Average Gains from Investment Securities over 5 years is -$6.5 million, with a median of $13.2 million recorded in 2025.
• Across the five-year window, Gains from Investment Securities jumped 1543.01% in 2023 and tumbled 2582.0% in 2024, its largest moves.
• Year by year, Gains from Investment Securities stood at -$513.3 million in 2022, then surged by 101.95% to $10.0 million in 2023, then sank by 2582.0% to -$248.2 million in 2024, then surged by 105.8% to $14.4 million in 2025, then jumped by 42.36% to $20.5 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $20.5 million, $14.4 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.